Skip to content

Research Study for Children With Salt Wasting Congenital Adrenal Hyperplasia

A Novel Therapeutic Modality for Congenital Adrenal Hyperplasia

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT00529841
Enrollment
7
Registered
2007-09-14
Start date
2007-01-31
Completion date
2008-09-30
Last updated
2015-09-14

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Adrenal Hyperplasia, Congenital

Keywords

Salt Wasting Congenital Adrenal Hyperplasia, Subcutaneous Hydrocortisone

Brief summary

The purpose of this study is to develop a more physiological approach to the management of children and adolescents with salt wasting Congenital Adrenal Hyperplasia. We will administer the glucocorticosteroid via insulin infusion pump to see whether this treatment will improve the serum hormone concentrations.

Detailed description

The adrenal gland is a small organ of the body. It produces very important chemicals called hormones. One of these hormones, cortisol (the stress hormone) helps the body fight diseases. The other hormone is the aldosterone helps to maintain the normal amount of salt and water in the body. The third type of hormones are the androgens or male hormones, which cause some of the changes during puberty, like the growth of body hair and pimples. The salt wasting Congenital Adrenal Hyperplasia or CAH disease is a disease of the adrenal gland. Patients with this disease cannot make cortisol or the aldosterone. As a result, their body cannot fight diseases and cannot keep normal amounts of salt and water in the body. At the same time, the gland makes too much of the male hormones, which is bad for the body because too much male hormone slows down growth, increases the growth of body hair, and causes pimples and abnormal period in girls. Patients with this disease have to take medications every day. However, the treatment does not work very well, because usually the patients do not have the right amount of hormone in their body. Usually the body gets too much hormone right after taking the pills. A couple of hours later the body has too little of the hormones, because in the meantime the body gets rid of the medication.The healthy adrenal gland makes the hormones throughout the day in different amounts. The patients with this disease take the medication only a couple of times a day. They take the Florinef tablet once a day and the Cortisol tablet two or three times a day. The treatment that we use today by mouth cannot copy the natural hormone productions of the adrenal gland. Because of this it does not make much of a difference in the patient's life. We would like to improve the treatment and find out the effect of a new treatment. In this study we will try to imitate the body's normal hormone production and will give the medication via an insulin pump to see if this treatment method will decrease the male hormones in the blood. This study will help us to develop a new and better treatment for children and adolescents.

Interventions

DRUGHydrocortisone sodium acetate

Subcutaneous administration of medication via insulin pump

Sponsors

Baylor College of Medicine
Lead SponsorOTHER

Study design

Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
3 Years to 18 Years
Healthy volunteers
No

Inclusion criteria

* Children with salt wasting CAH otherwise healthy without other chronic disease * Age: between 3 and 18 years of age * Body weight 23 kg (50 lbs) or above * Hemoglobin equal to or higher than 12 g/dl before the study * Supportive family environment

Exclusion criteria

* Age less than 3 or older than 18 years at the time of study * Other chronic disease * Hemoglobin less than 12 g/dl * Non-supportive family * Allergy to local anesthetics Criteria for study termination: If the subject's parents are unable to manage/operate the pump, the subject will be withdrawn from the study.

Design outcomes

Primary

MeasureTime frame
Serum 17-OHP concentration in the morning11 days

Secondary

MeasureTime frame
serum steroid hormone profiles11 days
serum blood glucosestudy days 2,3 and 11
serum sodiumstudy days 2,3 and 11

Countries

United States

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026